CurrentCignaPolicy N/A

Lofexidine Prior Authorization Policy

Defines Cigna's prior authorization requirements and coverage criteria for lofexidine (Lucemyra/generic) for treatment of opioid withdrawal in adults.

Policy Summary

PayerCigna

PolicyLofexidine Prior Authorization Policy

Policy CodePolicy N/A

Change TypeOperational (product naming and generic inclusion)

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document history of clonidine use demonstrating unacceptable toxicity or inadequate efficacy when prescribing lofexidine for opioid withdrawal.

SourceLink

POLICY UPDATE CHANGES

Policy name changed from Lucemyra Prior Authorization Policy to Lofexidine Prior Authorization Policy and generic lofexidine tablets were rolled into the policy.

14 daysmaximum approval duration for FDA-approved indication

Up to 14 daysrecommended max treatment

2025-07-23last review date

1 indicationcovered indication

Coverage Criteria for Lofexidine (Lucemyra)

Initial approval — FDA-approved indication

Covered when ALL of the following are met for opioid withdrawal symptoms

FDA-Approved Indication - Opioid Withdrawal Symptoms: A) Lofexidine is being used to facilitate abrupt opioid discontinuation; AND B) Patient has a history of clonidine use (e.g., patches, tablets) and experienced unacceptable toxicity and/or inadequate efficacy.approve for 14 days

Approvals are for 2 weeks (14 days).

Lofexidine (Lucemyra and generic lofexidine tablets) is not medically necessary for any uses other than the FDA‑approved indication. In particular, use of lofexidine for treatment of Cannabis Use Disorder (cannabis dependence) is considered not medically necessary based on available study evidence. A randomized, placebo‑controlled trial (n = 156) evaluating the combination of dronabinol and lofexidine for cannabis dependence over 11 weeks did not demonstrate efficacy.

Use of lofexidine for Cannabis Use Disorder (cannabis dependence) is explicitly considered not medically necessary.

Treatment Duration and Coding Notes

Policy Summary

PayerCigna

PolicyLofexidine Prior Authorization Policy

Policy CodePolicy N/A

Change TypeOperational (product naming and generic inclusion)

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document history of clonidine use demonstrating unacceptable toxicity or inadequate efficacy when prescribing lofexidine for opioid withdrawal.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is recommended for prescription benefit coverage of lofexidine. Approvals are provided for the duration noted.

Lucemyra (lofexidine tablets - US WorldMeds, generic)

Step Therapy

Step Therapy / Prerequisite

Approval requires use of lofexidine specifically to facilitate abrupt opioid discontinuation and documentation of a history of clonidine trial with unacceptable toxicity or inadequate efficacy.

Indication: abrupt opioid discontinuation
Prerequisite: history of clonidine use with documented unacceptable toxicity and/or inadequate efficacy
Approval duration: 14 days for opioid withdrawal symptoms

Documentation Required

Required Documentation and Coding

Coverage determinations require review of the member's specific benefit plan and applicable laws/regulations. Requests must include documentation of the FDA‑approved indication being treated, clinical rationale for use, prior clonidine trial details (dose/formulation, duration, and reason for discontinuation), and any supporting clinical records. Use most appropriate diagnosis and procedure codes when billing.

Document benefit plan applicability and applicable laws/regulations
Include indication being treated and clinical rationale
Provide prior clonidine trial details (dose/formulation, duration, toxicity or inefficacy)
Attach supporting clinical records and relevant dates
Use appropriate diagnosis/procedure codes

Denial Risk

General Denial Risk

Requests that do not meet the medical necessity criteria in this policy — including use for indications other than facilitating abrupt opioid discontinuation or lack of documentation of a clonidine trial with unacceptable toxicity/inadequate efficacy — may be denied.

Denial risk if not used for abrupt opioid discontinuation
Denial risk if no documented clonidine trial with unacceptable toxicity or inadequate efficacy
Denial risk if required documentation or applicable benefit coverage is not provided

Background

Lofexidine is a central alpha‑2 adrenergic agonist indicated to mitigate opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. It is typically dosed multiple times daily during the peak withdrawal period (first 5–7 days) and may be used for up to 14 days to manage withdrawal symptoms and support completion of abrupt discontinuation.

Opioid withdrawal symptoms vary by opioid half‑life and usually peak within days after last use; while rarely life‑threatening, symptoms and cravings can complicate completion of withdrawal, and alpha‑2 agonists such as lofexidine (and clonidine) may be used with other non‑narcotic medications to reduce these symptoms. For coverage, approvals for the FDA‑approved indication are provided for up to 14 days when specified criteria are met.

Definitions

inv-10: Definition — Lofexidine as a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults

Drug class and indicationLofexidine is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Adult indication onlyIndicated to facilitate abrupt opioid discontinuation in adults; dosing and duration guided by symptoms.

Usual dosing frequencyTypically dosed four times daily during the period of peak withdrawal symptoms.

inv-11: Definition — Opioid use disorder described as a primary, chronic and relapsing CNS disease characterized by pathological pursuit of reward and/or relief by substance use

DefinitionOpioid use disorder is a primary, chronic and relapsing central nervous system (CNS) disease of brain reward, motivation, memory, and related circuitry characterized by an individual pathologically pursuing reward and/or relief by substance use and other behaviors.

CourseChronic and relapsing — symptoms and severity vary by opioid half‑life and duration of use.

Withdrawal timingSymptoms usually begin two to three opioid half‑lives after last dose and peak within days depending on opioid half‑life.

OpenPayer